INIS
diseases
100%
patients
100%
carcinomas
100%
body composition
100%
muscles
80%
tubes
70%
feeding
70%
losses
70%
toxicity
50%
weight
50%
fats
30%
hazards
20%
doses
10%
therapy
10%
intake
10%
comparative evaluations
10%
males
10%
regression analysis
10%
interventions
10%
metabolism
10%
range
10%
guidelines
10%
multivariate analysis
10%
tolerance
10%
diet
10%
malnutrition
10%
impedance
10%
Keyphrases
Chemoradiation
100%
Body Composition
100%
Locally Advanced
100%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Tube Feeding
58%
Grip Strength
41%
Muscle Wasting
25%
Fat-free Mass Index
25%
Cisplatin
16%
Overall Survival
16%
Hazard Ratio
16%
Muscle Mass Loss
16%
Muscle Function
16%
Unfavorable Prognostic Factors
16%
Treatment Toxicity
16%
Human muscle
16%
Feeding Regime
16%
Treatment Outcome
8%
Patient Experience
8%
Weight Loss
8%
Total Weight Loss
8%
Baseline Measurements
8%
Treatment Initiation
8%
Treatment Tolerance
8%
Cachexia
8%
Bioelectrical Impedance Analysis
8%
Unplanned Hospitalizations
8%
Muscle Strength
8%
Muscle Weakness
8%
Nutritional Intake
8%
CRT-P
8%
Malnutrition
8%
Prognostic Factors
8%
Common Terminology Criteria for Adverse Events (CTCAE)
8%
Dose-limiting Toxicity
8%
Dutch Guideline
8%
Cetuximab
8%
Toxicity Grades
8%
Multivariate Cox Regression Analysis
8%
Addition Strategy
8%
Feeding Groups
8%
Oral nutrition
8%
Index Strength
8%
Targeting Metabolism
8%
Patient's Weight Loss
8%
Intake Strategy
8%
Day Range
8%
High Toxicity
8%
Survival Treatment
8%
Medicine and Dentistry
Disease
100%
Chemoradiotherapy
100%
Head and Neck Squamous Cell Carcinoma
100%
Hand Grip
41%
Prognostic Factor
25%
Muscle Atrophy
25%
Overall Survival
16%
Hazard Ratio
16%
Cisplatin
16%
Adverse Event
8%
Cohort Analysis
8%
Muscle Weakness
8%
Muscle Strength
8%
Cachexia
8%
Body Weight Loss
8%
Proportional Hazards Model
8%
Cetuximab
8%
Dietary Intake
8%
Patient Experience
8%
Carbetimer
8%
Bioelectrical Impedance Analysis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Chemoradiation Therapy
100%
Head and Neck Squamous Cell Carcinoma
100%
Muscle Atrophy
25%
Overall Survival
16%
Cisplatin
16%
Cohort Study
8%
Adverse Event
8%
Muscle Weakness
8%
Cachexia
8%
Cetuximab
8%
Carbetimer
8%
Food Science
Malnutrition
100%
Dietary Intake
100%